Ocular Therapeutix, Inc.
OCULNext catalyst
OTX-TKI
Neovascular Age-related Macular Degeneration
Get an email about OCUL's next catalysts
Track Ocular Therapeutix (OCUL) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 2 more upcoming events in our data (Phase 3 readout, PDUFA date).See the timeline
3 upcoming, 1 past
OTX-TKI Phase 3 Est. Readout
Estimated primary completion for OTX-TKI trial (NCT06495918) in Neovascular Age-related Macular Degeneration. Topline data typically follows completion by weeks to months.
SourceIntravitreal injection of axitinib hydrogel implant followed by a second intravitreal injection of the axitinib implant at Week 24 Phase 3 Est. Readout (HELIOS-3)
Estimated primary completion for Intravitreal injection of axitinib hydrogel implant followed by a second intravitreal injection of the axitinib implant at Week 24 trial (NCT07235085) in Non-Proliferative Diabetic Retinopathy. Topline data typically follows completion by weeks to months.
SourceFDA PDUFA Date Axpaxli
For wet age-related macular degeneration (wet AMD). NDA submitted. AI-extracted from: Ocular to submit Axpaxli NDA for wet AMD in Q4
SourceHow OCUL's past catalysts played out
Market Overview
Stock performance and key metrics
Intravitreal injection of axitinib hydrogel implant followed by a second intravitreal injection of the axitinib implant at Week 24
Non-Proliferative Diabetic Retinopathy
Single intravitreal injection of axitinib hydrogel implant followed by a mock (sham) injection procedure at Week 24
Non-Proliferative Diabetic Retinopathy
Ophthalmic Insert
Open Angle Glaucoma and Ocular Hypertension
Dextenza Ophthalmic Insert
Cataract
Travoprost
Open Angle Glaucoma
Dexamethasone
Allergic Conjunctivitis
OTX-TKI
Neovascular Age-related Macular Degeneration
OTX-TKI (axitinib implant)
Neovascular Age-Related Macular Degeneration
Punctum Plug
Post Ocular Surgical Inflammation and Pain
OTX-TP
Glaucoma
Controlled Insertion
Dry Eye Syndromes
OTX-CSI
Dry Eye Disease
OTX-DED
Dry Eye
OTX-TIC high dose Travoprost Intracameral Implant
Open Angle Glaucoma
OTX-DP (Dexamethasone punctum plug)
Ocular Inflammation and Pain
OTX-TIC low dose Travoprost Intracameral Implant
Open Angle Glaucoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Intravitreal injection of axitinib hydrogel implant followed by a second intravitreal injection of the axitinib implant at Week 24 | Phase 3 | Non-Proliferative Diabetic Retinopathy | - | - |
Single intravitreal injection of axitinib hydrogel implant followed by a mock (sham) injection procedure at Week 24 | Phase 3 | Non-Proliferative Diabetic Retinopathy | - | - |
Ophthalmic Insert | Phase 3 | Open Angle Glaucoma and Ocular Hypertension | - | - |
Dextenza Ophthalmic Insert | Phase 3 | Cataract | - | - |
Travoprost | Phase 3 | Open Angle Glaucoma | - | - |
Dexamethasone | Phase 3 | Allergic Conjunctivitis | - | - |
OTX-TKI | Phase 3 | Neovascular Age-related Macular Degeneration | - | - |
OTX-TKI (axitinib implant) | Phase 3 | Neovascular Age-Related Macular Degeneration | - | - |
Punctum Plug | Phase 3 | Post Ocular Surgical Inflammation and Pain | - | - |
OTX-TP | Phase 2 | Glaucoma | - | - |
Controlled Insertion | Phase 2 | Dry Eye Syndromes | - | - |
OTX-CSI | Phase 2 | Dry Eye Disease | - | - |
OTX-DED | Phase 2 | Dry Eye | - | - |
OTX-TIC high dose Travoprost Intracameral Implant | Phase 2 | Open Angle Glaucoma | - | - |
OTX-DP (Dexamethasone punctum plug) | Phase 2 | Ocular Inflammation and Pain | - | - |
OTX-TIC low dose Travoprost Intracameral Implant | Phase 2 | Open Angle Glaucoma | - | - |
Frequently asked questions
What is in Ocular Therapeutix, Inc.'s drug pipeline?→
CatalystAlert tracks 16 drug candidates in Ocular Therapeutix, Inc.'s (OCUL) pipeline across Phase 3, Phase 2. Its lead program is Intravitreal injection of axitinib hydrogel implant followed by a second intravitreal injection of the axitinib implant at Week 24 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Ocular Therapeutix, Inc.'s next FDA catalyst?→
Ocular Therapeutix, Inc.'s (OCUL) next tracked catalyst is a Phase 3 readout expected January 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track OCUL biotech catalysts?→
Add OCUL to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Ocular Therapeutix, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.
